Jeff Yass’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Jeff Yass’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,457	Closed	-$64.2K	–	13764
2023 Q1	$64.2K	Buy	+16,457	New	+$87K	﹤0.01%	11578
2022 Q3	–	Sell	-343	Closed	-$4K	–	14569
2022 Q2	$4K	Buy	+343	New	+$5.41K	﹤0.01%	12644
2022 Q1	–	Sell	-639	Closed	-$18.9K	–	14371
2021 Q4	$29K	Buy	+639	New	+$43.5K	﹤0.01%	12755

Other funds holding KRBP

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Jeff Yass's KRBP Position: Q2 2023 in Review

Jeff Yass sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q2 2023, closing a stake of 16,457 shares — an estimated $64.2K sold.

Jeff Yass first reported a position in KRBP in Q4 2021 and held it in 3 quarters. The position peaked at $64.2K in Q1 2023. 5 funds tracked by Wall St. Rank hold KRBP as of Q2 2023.

Jeff Yass reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jeff Yass sold 16,457 Kiromic BioPharma, Inc. Common Stock shares in Q2 2023, an estimated $64.2K.
Jeff Yass first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
Jeff Yass's Kiromic BioPharma, Inc. Common Stock position peaked at $64.2K in Q1 2023.
5 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.